Objective assessment of motor slowness in Huntington's disease: clinical correlates and 2-year follow-up - PubMed
Objective assessment of motor slowness in Huntington's disease: clinical correlates and 2-year follow-up
Jeroen P P van Vugt et al. Mov Disord. 2004 Mar.
Abstract
Functional disability of patients with Huntington's disease (HD) is determined by impairment of voluntary motor function rather than the presence of chorea. However, only few attempts have been made to quantify this motor impairment. By using a simple reaction time paradigm, we measured the time needed for movement initiation (akinesia) and execution (bradykinesia) in 76 HD patients and 127 controls. Akinesia and bradykinesia were already evident in early stages and increased linearly with increasing disease stage. Quantified motor slowness correlated with clinical impairment of voluntary movements but also with cognitive impairment and medication use. In patients without severe cognitive impairment, quantified motor slowness reflected clinical motor impairment more purely. During 1.9 years follow-up (range, 0.8-3.8 years), quantified akinesia and bradykinesia progressed concomitantly with progression of clinical impairment of voluntary movements, cognition, and functional capacity. However, rate of change in motor slowness did not discriminate between patients whose disease stage remained stable and those whose disease stage progressed. We conclude that the reaction time paradigm may be used to quantify akinesia and bradykinesia in HD, at least in patients without severe cognitive impairment. Although reaction and movement times increased in time, these measures failed to detect functionally important changes during our follow-up period.
Copyright 2004 Movement Disorder Society
Similar articles
-
Complex movement behaviour and progression of Huntington's disease.
Andrich J, Saft C, Ostholt N, Müller T. Andrich J, et al. Neurosci Lett. 2007 Apr 18;416(3):272-4. doi: 10.1016/j.neulet.2007.02.027. Epub 2007 Feb 11. Neurosci Lett. 2007. PMID: 17321683
-
Beste C, Konrad C, Saft C, Ukas T, Andrich J, Pfleiderer B, Hausmann M, Falkenstein M. Beste C, et al. Exp Neurol. 2009 Mar;216(1):148-57. doi: 10.1016/j.expneurol.2008.11.018. Epub 2008 Dec 10. Exp Neurol. 2009. PMID: 19111540
-
[Huntington chorea. Clinical correlations and preliminary neuropsychological data].
Fragassi NA, Stanzione M, Angelini R, Di Maio L. Fragassi NA, et al. Acta Neurol (Napoli). 1992 Aug-Dec;14(4-6):530-6. Acta Neurol (Napoli). 1992. PMID: 1293994 Italian.
-
Clinical neurophysiology of akinesia.
Hallett M. Hallett M. Rev Neurol (Paris). 1990;146(10):585-90. Rev Neurol (Paris). 1990. PMID: 2263821 Review.
-
[Neuropsychological deterioration in Huntington's disease].
Deus-Yela J, Pujol J, Espert R. Deus-Yela J, et al. Rev Neurol. 1997 Aug;25(144):1257-68. Rev Neurol. 1997. PMID: 9340161 Review. Spanish.
Cited by
-
Mühlbäck A, Frank W, Klempířová O, Bezdíček O, Schmitt L, Hofstetter N, Landwehrmeyer GB, Klempíř J. Mühlbäck A, et al. Arch Clin Neuropsychol. 2021 Jan 15;36(1):74-86. doi: 10.1093/arclin/acaa038. Arch Clin Neuropsychol. 2021. PMID: 32613239 Free PMC article.
-
Time processing in Huntington's disease: a group-control study.
Beste C, Saft C, Andrich J, Müller T, Gold R, Falkenstein M. Beste C, et al. PLoS One. 2007 Dec 5;2(12):e1263. doi: 10.1371/journal.pone.0001263. PLoS One. 2007. PMID: 18060059 Free PMC article.
-
Effectiveness of anti-psychotics and related drugs in the Huntington French-speaking group cohort.
Désaméricq G, Dolbeau G, Verny C, Charles P, Durr A, Youssov K, Simonin C, Azulay JP, Tranchant C, Goizet C, Damier P, Broussolle E, Demonet JF, Morgado G, Cleret de Langavant L, Macquin-Mavier I, Bachoud-Lévi AC, Maison P. Désaméricq G, et al. PLoS One. 2014 Jan 15;9(1):e85430. doi: 10.1371/journal.pone.0085430. eCollection 2014. PLoS One. 2014. PMID: 24454865 Free PMC article.
-
Despard J, Ternes AM, Dimech-Betancourt B, Poudel G, Churchyard A, Georgiou-Karistianis N. Despard J, et al. PLoS One. 2015 Aug 6;10(8):e0133709. doi: 10.1371/journal.pone.0133709. eCollection 2015. PLoS One. 2015. PMID: 26248012 Free PMC article.
-
Organoselenium bis selenide attenuates 3-nitropropionic acid-induced neurotoxicity in rats.
Bortolatto CF, Jesse CR, Wilhelm EA, Chagas PM, Nogueira CW. Bortolatto CF, et al. Neurotox Res. 2013 Apr;23(3):214-24. doi: 10.1007/s12640-012-9336-5. Epub 2012 Jun 28. Neurotox Res. 2013. PMID: 22739838
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical